发明名称 |
TREATMENT OF METASTIC BREAST CANCER |
摘要 |
The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positiv metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel. |
申请公布号 |
US2017029527(A1) |
申请公布日期 |
2017.02.02 |
申请号 |
US201615293165 |
申请日期 |
2016.10.13 |
申请人 |
Genentech, Inc. |
发明人 |
Paton Virginia;Blackwood Chirchir Anne;Klein Pam |
分类号 |
C07K16/30;A61K39/395;C07K16/28;A61K31/337;A61K45/06 |
主分类号 |
C07K16/30 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for the treatment of breast cancer, comprising administering to a HER2 positive metastatic breast cancer patient an effective amount of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody, and a taxane, wherein the patient did not receive prior chemotherapy or biologic therapy for their metastatic breast cancer. |
地址 |
South San Francisco CA US |